2-苯基嘧啶-4,5-二胺 | 21164-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-苯基嘧啶-4,5-二胺
• 英文名称: 2-phenyl-pyrimidine-4,5-diamine
• 英文别名: 2-phenyl-4,5-diaminopyrimidine；4,5-Diamino-2-phenyl-pyrimidin；4,5-Diamino-2-phenylpyrimidine；2-phenylpyrimidine-4,5-diamine
• CAS: 21164-35-2
• 化学式: C₁₀H₁₀N₄
• 分子量: 186.216
• InChiKey: OMUVXOQQNGVUJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-苯基嘧啶-4,5-二胺 、 生成
  参考文献：
  名称：

  Novel Sulfone Amide Amide Derivatives

  摘要：

  本发明涉及通式（I）的化合物：其中A、B、C和D分别独立地是甲烷基团或氮原子，所述甲烷基团可选地具有至少一个取代基，其中E表示以下式（E1）所代表的基团：R1表示较低的烷基或芳基，可选地具有一个或多个取代基，或表示与E的任意可连接位置相连的较低的烷基烯基，以及其他。本发明的化合物可用作治疗与NPY相关的各种疾病的药剂。

  公开号：

  US20080161326A1
• 作为产物：
  描述：

  5-硝基-2-苯基嘧啶 在 palladium 10% on activated carbon potassium tert-butylate 、 甲氧基胺盐酸盐 、 zinc(II) chloride 、 碳酸氢钠 、 氢气 作用下， 以 二甲基亚砜 、 水 、 乙酸乙酯 、 甲醇 为溶剂， 反应 1.67h， 以80%的产率得到2-苯基嘧啶-4,5-二胺
  参考文献：
  名称：

  [EN] NOVEL BENZIMIDAZOLE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE

  摘要：

  公开号：

  WO2004002986A3

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2013182612A1

  公开（公告）日：2013-12-12

  The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及通式(I)的化合物：其中RA、RB、RC、RD、m和n如描述和权利要求中所述，并且有效地且选择性地抑制葡萄糖转运蛋白1（GLUT1），以及制备该化合物的方法，包括含有该化合物的药物组合物和药物组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物的用途，以及在制备该化合物中有用的中间体化合物。
• Novel benzimidazole derivatives
  申请人：Otake Norikazu

  公开号：US20060205750A1

  公开（公告）日：2006-09-14

  The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

  本发明涉及一种式(I)的化合物：其中A、B、C和D分别独立表示氮或可选取代的甲烷基；E表示氮、甲烷基或羟基取代的甲烷基；n为0或1；T、U、V和W分别独立表示氮或可选取代的甲烷基；X为—N（SO2R4）—、—N（COR5）—或—CO—；Y为—C（R6）（R7）—、—O—或—N（R8）—，但当化合物（I）中E为氮，n为0，X为—CO—，Y为—O—时，该化合物被排除在外。此外，该化合物及其类似物可用作治疗与NPY相关的各种疾病的药物，例如心血管疾病如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等；中枢神经系统疾病如贪食症、抑郁症、焦虑症、癫痫、痴呆、疼痛、酗酒、戒断症状、生物钟紊乱、精神分裂症、记忆力减退、睡眠障碍、认知障碍等；代谢性疾病如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等；生殖系统疾病如不孕症、早产、性功能障碍等；胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等；例如动脉粥样硬化、性腺功能减退、高雄激素血症、多囊卵巢综合症（皮克威克综合症）、多毛症、胃肠道运动障碍、肥胖相关的胃食管反流、肥胖低通气综合症、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合症、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、周围血管疾病、猝死、胆囊疾病、癌症（乳腺、子宫内膜、结肠）、呼吸困难、高尿酸血症、生育能力下降、腰痛或麻醉风险增加等。
• Novel Sulfone Amide Amide Derivatives
  申请人：Otake Norikazu

  公开号：US20080161326A1

  公开（公告）日：2008-07-03

  The present invention relates to compounds of the general formula (I): wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1): R 1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others. The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.

  本发明涉及通式（I）的化合物：其中A、B、C和D分别独立地是甲烷基团或氮原子，所述甲烷基团可选地具有至少一个取代基，其中E表示以下式（E1）所代表的基团：R1表示较低的烷基或芳基，可选地具有一个或多个取代基，或表示与E的任意可连接位置相连的较低的烷基烯基，以及其他。本发明的化合物可用作治疗与NPY相关的各种疾病的药剂。
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：OTAKE NORIKAZU

  公开号：US20100048600A1

  公开（公告）日：2010-02-25

  The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

  本发明涉及一种式（I）的化合物：其中A、B、C和D独立地表示氮或可选取代的亚甲基；E表示氮、亚甲基或羟基取代的亚甲基；n为0或1；T、U、V和W独立地表示氮或可选取代的亚甲基；X为-N（SO2R4）-、-N（COR5）-或-CO-；Y为-C（R6）（R7）-、-O-或-N（R8）-，但当E为氮，n为0，X为-CO-，且Y为-O-时，化合物（I）被排除。此类化合物可用作治疗与NPY相关的各种疾病的药物，例如心血管疾病（如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等）、中枢神经系统疾病（如暴食症、抑郁症、焦虑症、癫痫、老年痴呆、疼痛、酗酒、戒毒、昼夜节律紊乱、精神分裂症、记忆障碍、睡眠障碍、认知障碍等）、代谢性疾病（如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等）、生殖系统或生殖障碍（如不孕症、早产、性功能障碍等）、胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等，例如动脉粥样硬化、性腺功能减退、高雄激素症、多囊卵巢综合征（匹克威克综合征）、多毛症、胃肠道运动障碍、肥胖相关胃食管反流、肥胖低通气综合征、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合征、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、外周血管疾病、猝死、胆囊疾病、癌症（乳腺、子宫内膜、结肠）、气短、高尿酸血症、生育能力受损、腰痛或麻醉风险增加等。
• PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS
  申请人：Wang Tiansheng

  公开号：US20110053916A1

  公开（公告）日：2011-03-03

  The present invention relates to compounds useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the inventions and

  本发明涉及用于治疗结核病的抑制剂化合物。该发明还提供了制备该发明化合物的方法。